In agreement with the in vitro results (Fig. S8A, B), immunoblotting analysis of tumor homogenates showed that shRNA-TTN-AS1 treatment led to downregulation of NRP-1, cyclin E, and CDK2, and upregulation of p27; while antagomiR-320a counteracted the effects of shRNA-TTN-AS1 (Fig. 4g). The gene discussed is CDK2; the disease is neoplasm.